https://biospectrumindia.com/rssfeed/states/west%20bengal west bengal https://biospectrumindia.com/news/115/28544/manipal-hospital-opens-first-of-its-kind-skull-base-institute-in-kolkata.html https://biospectrumindia.com/news/115/28544/manipal-hospital-opens-first-of-its-kind-skull-base-institute-in-kolkata.html Sat, 26 Sep 2026 14:57:19 +0530 Hidden deep within the human anatomy, where the brain, ears, eyes, major blood vessels and critical nerves converge, the skull base is among the most complex regions to treat surgically. Conditions affecting this delicate area often demand far more than a single-specialty approach, requiring the combined expertise of ENT specialists, neurosurgeons and oncological surgeons, supported by advanced surgical techniques and careful treatment planning. Recognising the need for such integrated care, Manipal Hospital EM Bypass, a unit of Manipal Hospitals Group, has launched the Manipal Skull Base Institute, the first of its kind in Eastern India, dedicated to the comprehensive management of complex skull base conditions and hearing disorders. The institute brings multiple specialties and advanced surgical expertise under one roof, enabling patients to access coordinated care spanning diagnosis, treatment, surgery, rehabilitation and long-term follow-up.  As part of its specialised offering, the institute will provide comprehensive cochlear implant care for individuals with severe to profound hearing loss who may not benefit adequately from conventional hearing aids, with the programme encompassing the complete continuum of care, from detailed hearing assessment and pre-operative evaluation to implant surgery, device activation, auditory rehabilitation and post-operative follow-up. With individualised treatment plans for both children and adults, the approach aims to support speech, language and learning in children while helping adults improve hearing, communication and quality of life. By bringing these specialised disciplines and services together, the institute aims to facilitate collaborative diagnosis, precise treatment planning and comprehensive, coordinated care for patients with complex skull base and hearing-related conditions. The institute will emphasise multidisciplinary evaluation, detailed diagnostic assessment, individualised treatment planning and advanced surgical management, depending on the patient's condition. By bringing together specialists from different disciplines, the centre aims to facilitate seamless decision-making for complex cases and provide patients with a comprehensive continuum of care. ]]> https://biospectrumindia.com/news/115/28043/iit-kharagpur-develops-climate-informed-dengue-risk-assessment-framework.html https://biospectrumindia.com/news/115/28043/iit-kharagpur-develops-climate-informed-dengue-risk-assessment-framework.html Tue, 30 Jun 2026 13:50:13 +0530 Researchers at the Indian Institute of Technology (IIT) Kharagpur have developed CliMed, a climate-informed and spatially explicit modelling framework for dengue risk assessment over India. The model brings together daily climate information, land-use characteristics, human population data, settlement context and mosquito-species suitability to generate interpretable risk signals for Aedes-borne dengue transmission. Dengue risk is shaped by several interacting conditions. Temperature influences mosquito biting, development, survival and the time required for the virus to become transmissible inside the mosquito. Rainfall can create breeding opportunities, while very heavy rainfall may also disturb immature stages. Humidity affects mosquito activity and survival. Land-use, settlement pattern and population distribution determine whether suitable mosquito conditions are likely to translate into meaningful human exposure. CliMed has been designed to read these factors together, rather than treating dengue risk as a simple statistical association between weather and reported cases. CliMed is intended to support preparedness by adding an environmental and biological layer to dengue risk interpretation. Reported case counts remain essential, but they may be delayed, unevenly recorded or influenced by testing and reporting practices. CliMed therefore provides a complementary view: it identifies days and locations where climate, vector ecology and exposure conditions may be becoming more favourable for transmission. CliMed should be understood as a research and decision-support framework. It does not diagnose dengue, replace surveillance data or predict confirmed clinical cases by itself. Its outputs are interpretable risk signals that should be compared with field surveillance, local vector information, public-health records and expert review before operational decisions are made. The immediate goal is to strengthen dialogue between climate scientists, epidemiologists, public-health officials and local administrations by providing transparent maps and indicators that explain why a place or season may deserve closer attention. ]]> https://biospectrumindia.com/news/115/27171/yellow-fertility-partners-with-care-ivf-to-strengthen-footprints-across-east-and-north-east-region.html https://biospectrumindia.com/news/115/27171/yellow-fertility-partners-with-care-ivf-to-strengthen-footprints-across-east-and-north-east-region.html Mon, 12 Jan 2026 00:00:00 +0530 Yellow Fertility, one of India’s most affordable fertility care providers, has partnered with CARE IVF to expand access to structured and evidence-based fertility treatment across Eastern and North-Eastern India, where demand for advanced reproductive healthcare is steadily rising. As part of the partnership, the two organisations plan to open 8 additional centres across key locations in the East and North-East over the next two years. The expansion aims to improve access to affordable in-vitro fertilisation (IVF) and assisted reproductive technology (ART) services, while reducing the need for patients to travel long distances for treatment. The partnership will begin with collaboration across two existing centres operated by CARE IVF in Kolkata. These centres offer a comprehensive range of fertility services, including in-vitro fertilisation (IVF), intrauterine insemination (IUI), fertility preservation, advanced assisted reproductive technology (ART) procedures and personalised treatment pathways. Patients are expected to benefit from standardised clinical protocols, experienced medical teams and integrated care systems designed to improve treatment outcomes. Commenting on the partnership, Ambika Bhaik, CEO of Yellow Fertility, said the collaboration reflects the company’s long-term and measured approach to expansion. “Our focus has been on scaling in a manner that does not compromise clinical quality or ethical standards. CARE IVF brings strong regional insights and deep clinical expertise, making it an important ecosystem partner as we expand our footprint in Eastern and North-Eastern India." Dr Mukesh Sirohia- Partner/Director, Care IVF, said Eastern and North-Eastern India are emerging as important markets for fertility care, driven by changing demographic trends and rising awareness. ]]> https://biospectrumindia.com/news/115/27052/scientists-at-bose-institute-create-glowing-protein-to-monitor-gene-editing.html https://biospectrumindia.com/news/115/27052/scientists-at-bose-institute-create-glowing-protein-to-monitor-gene-editing.html Wed, 10 Dec 2025 00:00:00 +0530 Scientists at the Bose Institute in Kolkata have created a CRISPR protein that can help scientists observe molecular scissors called the Cas9 enzyme as it enables them to edit the genome using the CRISPR – Cas9system for the treatment of genetic diseases, including cancer. CRISPR-Cas9 was designed to cut and correct DNA with precision. Scientists have not been able to observe Cas9 in real time in living cells, however. Traditional detection methods rely on connecting or breaking open cells, making this process impossible to track. In the new study, the researchers have combined Cas9 with a split nano-luciferase enzyme derived from a deep-sea shrimp protein to create a bio-luminous version of Cas9 called GloCas9, which glows inside cells. By combining gene editing with light emission, GlockaS9 is leading the way in the emerging field of theratracking, a unique example of looking at molecular gene therapy in a moving state. This invention brings us closer to a future where scientists will not only be able to fine-tune genes but also witness the process of treatment firsthand. ]]> https://biospectrumindia.com/news/115/26816/manipal-institute-of-nephrology-and-urology-opens-in-kolkata.html https://biospectrumindia.com/news/115/26816/manipal-institute-of-nephrology-and-urology-opens-in-kolkata.html Fri, 17 Oct 2025 00:00:00 +0530 Manipal Hospitals Kolkata has made a major advancement in the field of specialised patient care with the launch of the Manipal Institute of Nephrology and Urology (MINU) in Kolkata, joining its established network of centres in Bengaluru, Goa, Mangalore, Jaipur, Manipal, Pune, Delhi, Gurugram, Ghaziabad, and Vijayawada.  Combining cutting-edge technology with expert, patient-centric medical care, the new institute will serve as a comprehensive one-stop destination for the diagnosis, treatment, and management of kidney and urinary tract disorders. The inauguration also featured a special health awareness session for senior citizens, focusing on kidney and urology health, preventive strategies, and lifestyle management reinforcing Manipal Hospitals’ continued commitment to community well-being and preventive healthcare.  The experts shared valuable insights on maintaining kidney and urology health, highlighting the importance of early detection, regular screening, and lifestyle management. They also interacted with senior citizens, addressing common concerns, explaining preventive measures, and guiding them on managing chronic kidney and urinary conditions. Dr H. Sudarshan Ballal, Chairman, Manipal Health Enterprise Pvt. Ltd. shared, “The launch of the Manipal Institute of Nephrology and Urology (MINU) in Kolkata marks our 11th centre under this specialised vertical, following its remarkable success across South India and other regions." Dr Arghya Majumdar, Director & Head – Nephrology, Manipal Hospital, Dhakuria, shared, “The launch of this institute is a major milestone in making advanced nephrology and urology care more accessible to the people of Eastern India. The Manipal Institute of Nephrology and Urology brings together a multidisciplinary team of experts across all our units, supported by a unified patient database and state-of-the-art diagnostic technology. This integrated model allows us to provide seamless, coordinated, and patient-centric care, from early detection to advanced treatment and long-term management." ]]> https://biospectrumindia.com/news/115/26663/redcliffe-labs-strengthens-presence-in-west-bengal-with-new-diagnostic-lab-in-midnapore.html https://biospectrumindia.com/news/115/26663/redcliffe-labs-strengthens-presence-in-west-bengal-with-new-diagnostic-lab-in-midnapore.html Wed, 10 Sep 2025 00:00:00 +0530 Redcliffe Labs, a purpose-driven pan-India omnichannel diagnostics service provider, has expanded its footprint in West Bengal with a new state-of-the-art diagnostic laboratory in Midnapore. With this addition, Redcliffe Labs strengthens its presence across East and West Midnapore and neighboring towns, further solidifying its commitment to providing India with access to quality diagnostics. The new facility in Midnapore, located in Sadar District's Miya Bazar, is aligned with the company's strategic focus on enhancing its reach in Tier II and Tier III regions. By combining advanced infrastructure with strong on-ground networks, Redcliffe Labs is addressing the growing demand for high-quality diagnostic services beyond major metropolitan centres. The advanced laboratory, equipped with the latest diagnostic technology, will bridge accessibility gaps and deliver accurate reports with minimal turnaround time. Redcliffe Labs offers a broad spectrum of diagnostic capabilities across biochemistry, hematology, immunoassays, clinical pathology, serology, and hormones. Patients can conveniently access these services through walk-ins and receive accurate reports, as per NABL & ISO guidelines, within the minimum possible turnaround time. Strategically located in Midnapore, the laboratory will extend services not only to residents of the city but also to surrounding areas, including Khargapur, Jhargram, Contai, Ghatal, Tamluk, and Haldia. The lab is headed by Dr. Manatosh Mandal, a seasoned pathologist with over 12 years of experience, whose expertise and leadership will ensure seamless diagnostic operations and reporting. Speaking about the launch, Aditya Kandoi, Founder & CEO, Redcliffe Labs, said, “Our purpose has always been to give every Indian the right to quality diagnostics. With the launch of our Midnapore laboratory, we are bridging the diagnostic gap that still exists beyond metros. People in Tier 2, Tier 3 cities, and smaller towns deserve the same level of accuracy, convenience, and preventive care as those in developed cities. This expansion is a step towards making advanced diagnostics truly inclusive and accessible for everyone across Bharat.   ]]> https://biospectrumindia.com/news/115/26589/scientists-in-kolkata-explore-use-of-giant-antibody-for-bracing-against-bacterial-toxins.html https://biospectrumindia.com/news/115/26589/scientists-in-kolkata-explore-use-of-giant-antibody-for-bracing-against-bacterial-toxins.html Mon, 25 Aug 2025 00:00:00 +0530 A recent study from researchers at the S.N. Bose National Centre for Basic Sciences (SNBNCBS) in Kolkata, an autonomous institute of the Department of Science and Technology (DST) reveals that IgM not only binds to pathogens but can also mechanically stabilise bacterial toxins, preventing them from harming our cells. This could inspire new therapies by designing antibodies that mechanically stiffen dangerous proteins and disarming them. The research focused on Protein L, a molecule from the bacterium Finegoldia magna. Protein L is known as a “superantigen” because it can bind antibodies in unusual ways, potentially disrupting normal immune function. What makes this study remarkable is its use of single-molecule force spectroscopy — a cutting-edge technique that applies tiny, precise forces to individual molecules to see how they behave under stress. The scientists discovered that when IgM binds to Protein L, it significantly increases the protein’s mechanical stability. In simple terms, IgM acts like a brace, making it harder for the protein to unfold or break apart under force. This effect was concentration-dependent — higher amounts of IgM gave Protein L more resistance to mechanical stress. The team also used computer simulations to explore why this happens. They found that IgM’s multiple binding sites can engage Protein L at several points simultaneously, creating a synergistic stabilizing effect. This is different from smaller antibodies, which lack the same stabilising power. ]]> https://biospectrumindia.com/news/115/25700/sodexo-strengthens-healthcare-technology-management-with-advanced-facility-in-kolkata.html https://biospectrumindia.com/news/115/25700/sodexo-strengthens-healthcare-technology-management-with-advanced-facility-in-kolkata.html Wed, 19 Feb 2025 00:00:00 +0530 With the increasing reliance on sophisticated medical technology, regular and efficient maintenance of biomedical equipment has become critical to ensure optimised healthcare outcomes for patients. In response to this growing need, Sodexo India has inaugurated a new, state-of-the-art Healthcare Technology Management (HTM) facility in Kolkata, equipped with specialised labs to support the maintenance of up to 5 lakh medical devices.  Featuring 6 specialised labs, supported by a dedicated team of more than 270 technical professionals and backed by an extensive network & partnerships with original equipment manufacturers (OEMs), this facility is designed to enhance the service efficiency for advanced testing, repair and maintenance capabilities across a range of biomedical equipments. With the new facility, Sodexo will ensure an impressive 99% uptime, delivering on its promise of reliable service and minimizing equipment downtime, providing the much-needed support to healthcare providers in for optimal delivery of health and care services across the state of West Bengal and widen the scope of operations across markets. The new facility will be covering 100% of the public health care set ups, namely government hospitals, small & medium diagnostics centers and medical colleges in Presidency region, Burdwan and Jalpaiguri. Additionally, it will enable Sodexo to scale up its HTM operations and support the expansion of biomedical equipment maintenance in other markets. ]]> https://biospectrumindia.com/news/115/25521/global-cloud-cayr-launches-health-management-services-in-kolkata.html https://biospectrumindia.com/news/115/25521/global-cloud-cayr-launches-health-management-services-in-kolkata.html Wed, 08 Jan 2025 00:00:00 +0530 Global Cloud Cayr (GCC), an innovative healthcare startup founded by an international team of doctors and technologists, has officially launched its operations in Kolkata.  This milestone marks the start of GCC’s mission to revolutionise healthcare delivery through a proactive, holistic, and technology-integrated approach. Designed to cater to individuals, families, and the elderly, including those managing chronic conditions, GCC brings personalized healthcare services directly to their homes or preferred locations. Combining virtual consultations with in-person services, GCC focuses on prevention, wellness, and participant-centric care to ensure accessible, effective, and empathetic healthcare. Its unique model is designed to address the growing need for personalized, comprehensive health-management solutions, particularly in the face of rising chronic diseases and lifestyle-related health challenges. GCC offers a wide range of services tailored to meet diverse healthcare needs. These include preventive health and wellness management through monitoring and early intervention, chronic disease management with personalised care plans for long-term conditions such as diabetes and heart disease, acute healthcare packages for addressing short-term illnesses or injuries, and emergency support for critical health situations. ]]> https://biospectrumindia.com/news/115/25506/iit-guwahati-develops-innovative-injectable-hydrogel-for-targeted-breast-cancer-therapy.html https://biospectrumindia.com/news/115/25506/iit-guwahati-develops-innovative-injectable-hydrogel-for-targeted-breast-cancer-therapy.html Sat, 04 Jan 2025 00:00:00 +0530 In a multi-institutional research led by researchers from Indian Institute of Technology Guwahati (IIT-G) and Bose Institute Kolkata, an advanced injectable hydrogel has been developed for localised cancer treatment. This innovative hydrogel-based therapy delivers anti-cancer drugs directly to tumor sites, significantly reducing the side effects typically associated with conventional cancer treatments. Hydrogels are water-based, three-dimensional polymer networks capable of absorbing and retaining fluids. Their unique structure mimics living tissues, making them suitable for biomedical applications. This newly developed hydrogel acts as a stable reservoir for anti-cancer drugs and releases them in a controlled manner, responding to specific conditions in the tumor microenvironment. The hydrogel, composed of ultra-short peptides – biocompatible and biodegradable building blocks of proteins – is designed to remain insoluble in biological fluids, ensuring it stays localized at the injection site. It responds to elevated glutathione (GSH) levels, a molecule abundant in tumor cells. Upon encountering high GSH levels, the hydrogel triggers a controlled drug release directly into the tumor, minimizing its interaction with healthy tissues and reducing systemic side effects. In preclinical trials on a murine model of breast cancer, the hydrogel showcased remarkable efficacy. A single injection of the hydrogel, loaded with the chemotherapy drug Doxorubicin, resulted in a ~75% reduction in tumor size within 18 days. Crucially, the hydrogel remained localised at the tumor site, steadily releasing the drug over time without causing detectable side effects on other organs. This innovative delivery system enhances the drug's effectiveness while reducing the required dosage, thus minimising toxicity. ]]> https://biospectrumindia.com/news/115/25409/iit-kharagpur-partners-with-tcs-to-launch-advanced-research-centre-for-innovation-in-digital-health-robotics-intelligent-systems.html https://biospectrumindia.com/news/115/25409/iit-kharagpur-partners-with-tcs-to-launch-advanced-research-centre-for-innovation-in-digital-health-robotics-intelligent-systems.html Fri, 29 Nov 2024 00:00:00 +0530 The Indian Institute of Technology (IIT) Kharagpur (KGP) has partnered with Tata Consultancy Services (TCS), a global leader in IT services, consulting, and business solutions to set up an advanced research centre to produce high-quality research in the areas of digital health, robotics and intelligent systems leveraging cutting-edge computing, embedded systems, and artificial intelligence (AI). Located in IIT Kharagpur Research Park in New Town, Kolkata, the TCS Research Centre will feature three state-of-the-art laboratories where over 150 TCS scientists will explore cutting-edge technologies and push the boundaries of innovation. The laboratories will be in the domains of – Sensing and Communications, Edge Computing and Analytics, and Robotics and Visual Computing. Researchers will have access to state-of-the-art equipment at the centre enabling them to accelerate innovations in cutting-edge technologies such as edge computing, embedded systems and Artificial Intelligence.  The centre will anchor TCS-funded research programmes that will be launched in partnership with academic partners, including IIT KGP. The TCS Research Centre at IIT KGP will also boast of a customer experience centre where TCS clients across industries such as mining, agriculture, mobility, healthcare, manufacturing, and retail can gain exclusive experience of original research concepts by TCS. Workshops held at the customer experience centre will be open to external participation where TCS scientists, industry subject matter experts as well as the IIT KGP faculty will collaborate to find solutions to industry problems. Building on the strong relationship shared by TCS and IIT KGP, this centre will serve as a pioneer for setting-up similar labs in the future.   ]]> https://biospectrumindia.com/news/115/25382/iit-kharagpur-partners-with-z21-ventures-to-launch-startup-accelerator-programme-kgp-forge-entrepreneur.html https://biospectrumindia.com/news/115/25382/iit-kharagpur-partners-with-z21-ventures-to-launch-startup-accelerator-programme-kgp-forge-entrepreneur.html Sat, 23 Nov 2024 00:00:00 +0530 In a powerful move to spark innovation and drive entrepreneurship among the brightest minds in India, Rajendra Mishra School of Engineering Entrepreneurship, Indian Institute of Technology (IIT) Kharagpur (KGP) has joined forces with z21 Ventures, an early-stage, operator-led venture capital firm founded by esteemed IIT Kharagpur alumni. This partnership heralds the launch of a ground-breaking startups accelerator programme tailored for final-year students, setting the stage for a new era of entrepreneurial excellence. Designed to harness the immense talent at KGP and transform bold ideas into market-ready ventures, the accelerator will offer participants unparalleled access to mentorship, funding, and top-tier resources. With a focus on building technical and scalable solutions to tackle global challenges, this programme aims to blend IIT Kharagpur’s cutting-edge research with z21 Ventures’ proven investment expertise, empowering student entrepreneurs to create world-changing impact. The accelerator will welcome up to 10 dynamic teams in its inaugural cohort, equipping them with year-round mentorship, strategic guidance, and seed funding to bring their concepts to life. Participants will benefit from z21 Ventures’ vibrant network of industry operators, successful founders, and seasoned advisors, all dedicated to steering them toward market success. Additionally, IIT Kharagpur will offer crucial infrastructure support post-graduation, ensuring that the journey from ideation to implementation continues seamlessly. The accelerator is open to B.Tech, M.Tech, and PhD students in their final year, underscoring a commitment to inclusivity and interdisciplinary innovation. Raj Singh, General Partner at z21 Ventures said, “Currently, there are fewer than 20 unicorns with roots at IIT KGP, including Persistent Systems, Rubrik, Innovaccer, and Swiggy. Our goal is to supercharge that number to 100 in the coming years.”   About IIT Kharagpur: ]]> https://biospectrumindia.com/news/115/25332/iit-kharagpur-inks-mou-with-central-council-for-research-in-homeopathy.html https://biospectrumindia.com/news/115/25332/iit-kharagpur-inks-mou-with-central-council-for-research-in-homeopathy.html Fri, 08 Nov 2024 00:00:00 +0530 Indian Institute of Technology Kharagpur (IIT KGP) has signed a Memorandum of Understanding (MoU) with Central Council for Research (CCRH) in Homeopathy on a collaborative study between IIT KGP and CCRH on the project titled “Fourier Transform Infra-Red (FTIR) Spectroscopic Study and Raman Study in Homeopathic Potentised Medicines and Characterisation, Standardisation and Analysis of the Imponderable Medicines (X-Ray, Electricity, Magnetis Polus, Australis etc.). The study include research activities, research schemes on Clinical Verification Research, Clinical Research, Drug Proving etc. The MoU was signed by Dr Subhash Kaushik, Director General, CCRH and Prof. Rintu Banerjee, Deputy Director, IIT Kharagpur in the presence of Prof. V. K. Tewari, Director, IIT Kharagpur. “A project based MoU has been signed between CCRH and IIT Kharagpur to undertake a fundamental research project on FTIR and Raman Study in Homeopathic Potentised Medicines and Characterisation and Analysis of the Imponderabilia Medicines,” said Dr Subhash Kaushik, Director General, CCRH. The period of the project is for 3 years. All the patents will be registered with the help of National Research Development Corporation (NRDC) with joint ownership. Both the institute shall consult each other for any publication in respect to the project which shall be a joint publication. Prof. V K Tewari, Director, IIT Kharagpur stated, “This MoU will be instrumental in the study of Homeopathic Potentized Medicines. We need to channelise the research projects that will give us the scope to develop and augment the field of medicine through technological convergence. In this study, Raman spectroscopy can be used to study the vibrational spectra of homeopathic medicines.”   ]]> https://biospectrumindia.com/news/115/24759/sbi-foundation-and-cbm-india-join-forces-to-combat-avoidable-blindness-in-howrah-west-bengal.html https://biospectrumindia.com/news/115/24759/sbi-foundation-and-cbm-india-join-forces-to-combat-avoidable-blindness-in-howrah-west-bengal.html Wed, 12 Jun 2024 00:00:00 +0530 CBM India, in partnership with SBI Foundation, has announced the Project 'SBIF Eye Care', aimed at reducing avoidable blindness in the Howrah district of West Bengal. The two-year project, spanning from March 2024 to February 2026, focuses on delivering inclusive, accessible, and affordable eye care services. Covering 12 blocks in the Howrah district, the project addresses a critical public health concern and a leading cause of blindness worldwide- cataracts. Several factors contribute to this challenge- the need to expand access to eye health services, low awareness about cataract symptoms and treatment options, the growing demand for more surgical capacity and infrastructure, and the limited access to follow-up care, medications, and rehabilitative services. The project addresses these challenges and prioritises sight-restoring procedures, targeting to perform 3,000 free cataract surgeries for people from marginalised communities. SBIF has been a pioneer in cataract care projects pan India; their programme aims to improve access to healthcare and help those in need of cataract surgery. Apart from this, the initiative aims at raising awareness about prevailing eye care issues, their prevention, and care, indirectly benefitting over 1,76,000 people, and offering eye screenings, counseling, and safety measures for eye care to over 30,000 individuals, including children and adults with disabilities. These goals will be achieved through a multifaceted approach, leveraging CBM India's Inclusive Vision Centers, eye screening camps, awareness camps, and door-to-door community eye screenings.   ]]> https://biospectrumindia.com/news/115/24468/zeno-health-acquires-kolkata-based-startup-tablt-pharmacy.html https://biospectrumindia.com/news/115/24468/zeno-health-acquires-kolkata-based-startup-tablt-pharmacy.html Thu, 04 Apr 2024 00:00:00 +0530 Zeno Health, one of India’s leading omni channel platform for quality and affordable generic medicines, has announced the acquisition of Kolkata-based startup Tablt  Pharmacy. As part of its expansion plans, Zeno Health along with Tablt will be strengthening its reach in the states of West Bengal, Odisha, Bihar and Jharkhand. Tablt, an online pharmacy startup, has been operating in Tier 2 to Tier 6 geographies in Eastern India. It operates through nearly 300 franchises across the Eastern Indian states of West Bengal, Bihar, Jharkhand, and Odisha and has served more than 2 lakh consumers so far. Girish Agarwal, Co-founder of Zeno Health said, "Zeno Health is on a mission to democratize healthcare across India and recently raised $25 million in a Series C fund round. As we aim to reach and serve more than 1 crore consumers every month, we are also aspiring to reduce their healthcare expenditures by 50%. Thus, our merger with Tablt and their excellent team will expedite our journey to rural and semi-urban areas, addressing the immense need for generic medicines." Zeno Health operates a expansive network of 180 omnichannel stores spanning Mumbai and the entire expanse of Maharashtra. ]]> https://biospectrumindia.com/news/115/24358/medikabazaar-inaugurates-new-central-distribution-centre-in-kolkata.html https://biospectrumindia.com/news/115/24358/medikabazaar-inaugurates-new-central-distribution-centre-in-kolkata.html Mon, 11 Mar 2024 00:00:00 +0530 Mumbai-based startup Medikabazaar, a leading B2B online platform serving the healthcare industry, has officially opened its new Central Distribution Centre (CDC) in Kolkata  The establishment of the Central Distribution Centre in Kolkata symbolises Medikabazaar's commitment to expanding its presence in the eastern region of India. By enhancing its footprint, the company aims to bolster its supply chain network and further its dedication to ensuring that healthcare services are accessible and affordable to all. Vivek Tiwari, Co-founder and CEO of Medikabazaar, said, "The opening of our CDC in Kolkata marks a significant milestone for Medikabazaar as we aim to better serve the healthcare industry in the eastern region of India. This initiative reflects our ongoing efforts to strengthen our supply chain network and enhance our support for healthcare providers in this region."  The new Central Distribution Centre in Kolkata is poised to play a pivotal role in Medikabazaar's mission to streamline healthcare supply chain operations and foster industry growth in the region.    ]]>